Department of Palliative Care, University Hospital Jena, Friedrich-Schiller University, Jena, Germany.
Comprehensive Cancer Center Central Germany (CCCG), Cologne, Germany.
Ann Hematol. 2024 May;103(5):1753-1763. doi: 10.1007/s00277-024-05726-8. Epub 2024 Mar 28.
Integrating palliative care into the treatment of patients with advanced hematological malignancies (HM) remains challenging. To explore treating physicians' perspectives on current palliative care practice and to evaluate factors influencing integration, we conducted a nationwide online survey. Based on literature and expert review, the survey addressed the importance of palliative care, communication about life-threatening conditions, challenges in establishing goals of care, and factors influencing the integration of palliative care. 207 physicians treating patients with HM in Germany participated. We used standard descriptive statistics to analyze quantitative data and a content structuring approach. Most physicians considered palliative care in HM to be very important (60.6%) and discussed life-threatening conditions with more than half of their patients (52%), especially when goals of care were changed (87.0%) or when patients raised the topic (84.0%). Disease-related factors, different professional perspectives on prognosis, and patient hopes were the main barriers to changing goals of care, but collaboration with colleagues and multidisciplinary teams provided important support. Time constraints were identified as the main barrier to integrating palliative care. The majority worked well with palliative care teams. Referral processes and conditions were perceived as minor barriers. The study highlights the need to address barriers to integrating palliative care into the management of patients with advanced HM. Future research should aim at optimizing palliative care for patients with HM.
将姑息治疗纳入晚期血液病(HM)患者的治疗仍然具有挑战性。为了探讨治疗医生对当前姑息治疗实践的看法,并评估影响整合的因素,我们进行了一项全国性的在线调查。基于文献和专家审查,该调查涉及姑息治疗的重要性、与危及生命情况的沟通、确定治疗目标的挑战以及影响姑息治疗整合的因素。207 名在德国治疗 HM 患者的医生参与了调查。我们使用标准描述性统计方法分析定量数据,并采用内容结构方法。大多数医生认为 HM 中的姑息治疗非常重要(60.6%),并与一半以上的患者讨论危及生命的情况,尤其是在改变治疗目标(87.0%)或患者提出该话题时(84.0%)。疾病相关因素、不同专业对预后的看法以及患者的希望是改变治疗目标的主要障碍,但与同事和多学科团队的合作提供了重要支持。时间限制被认为是整合姑息治疗的主要障碍。大多数医生与姑息治疗团队合作良好。转诊流程和条件被认为是较小的障碍。这项研究强调了需要解决将姑息治疗纳入晚期 HM 患者管理中的障碍。未来的研究应旨在优化 HM 患者的姑息治疗。